View Rome, Italy Final Program

Total Page:16

File Type:pdf, Size:1020Kb

View Rome, Italy Final Program 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS CONGRESS OF PARKINSON’S DISEASE 8TH INTERNATIONAL TABLE OF CONTENTS Invitation . .2 Acknowledgements . .4 Organization . .5 MDS Committees and Task Forces . .8 International Congress Registration and Venue . 11 International Congress Information . .12 Continuing Medical Education . .12 Evaluations . .12 Press Room . .13 Social Events . .14 Program at a Glance . .17 Scientific Sessions . .18 Faculty . .38 Committee and Task Force Meetings . .41 Exhibitor Information and Directory . .42 Floor Plan and Meeting Space . .46 Map of Rome . .51 Poster Session 1 . .52 Poster Session 2 . .63 Poster Session 3 . .73 Poster Session 4 . .83 THE CONGRESS IS UNDER THE AUSPICES OF: The President of the Italian Republic The Prime Minister of the Italian government The National Institute of Health (ISS) The National Research Council (CNR) The City of Rome The School of Medicine and Surgery, University of Rome “La Sapienza” The Italian Society of Neurology 1 THE MOVEMENT DISORDER SOCIETY INVITATION Dear Colleagues, Rome, Italy On behalf of the Officers and International Executive Committee of The Movement Disorder Society, welcome to the 8th International Congress of Parkinson’s Disease and Movement Disorders. I would like to thank the faculty and the members of the Congress Scientific Program Committee for this exemplary scientific program and for their contribution to the International Congress. The International Congress week begins with a variety of Kickoff Seminars, which are supported through unrestricted educational grants from industry. The week continues with a wide array of plenary sessions, parallel sessions, seminars and video dinners. Poster sessions are unopposed and, to further serve our participants, time has also been allotted for 16 poster platform presentations. I would like to thank the International Congress Oversight Committee and the Congress Organizing Committee for all of their hard work over the past two years. Their dedication in planning has allowed us to offer International Congress attendees the best that Rome has to offer. The social program will include a Sunday Opening Ceremony which will be held on the roof top terrace of the Palazzo dei Congressi. This event offers attendees the opportunity to greet each other while taking in the exquisite tastes and talents of Italy. The Congress Gala Event takes place at the Palazzo Brancaccio, offering a mix of Roman Patrician architecture, as well as enchanting gardens. In closing, I would like to thank all of the International Congress attendees for their participation in the success of the 8th International Congress. Sincerely, C. Warren Olanow President 2 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS CONGRESS OF PARKINSON’S DISEASE 8TH INTERNATIONAL INVITATION Dear Colleagues, It is my pleasure to welcome you to the 8th International Congress of Parkinson’s Disease and Move- ment Disorders. As one of the world’s most beautiful cities, Rome is an ideal venue for the Interna- tional Congress and I hope that you will enjoy all that the city has to offer. The photograph on the front page shows the Statue of the Nile, part of the Fountain of the Rivers created in 1651 by Gian Lorenzo Bernini and commissioned by Pope Innocenzo X. The Fountain is located in the middle of Piazza Navona and is one of the finest symbols of Baroque art. Its importance lies in the way the sculptor has fused figures, statues, landscapes, and water into one of his most imposing creations. The mass of rocks and grottoes forming the fountain is surmounted by a tall obelisk. At the four corners are colossal figures of the rivers Danube, Ganges, Nile and Plate, repre- senting the four quarters of the globe. With this symbolism in mind, I welcome participants from all over the world. The aim of the Interna- tional Congress is to increase our knowledge in the field of Movement Disorders by sharing global research and perspectives. In line with MDS tradition, the scientific program is informative, compre- hensive and innovative, including plenary session lectures, parallel sessions, platform presentations, abstract poster presentations, seminars and video dinners. On behalf of the Congress Organizing Committee and The Movement Disorder Society, welcome to Rome. Professor Alfredo Berardelli Chair, Congress Organizing Committee 3 THE MOVEMENT DISORDER SOCIETY ACKNOWLEDGEMENTS The Movement Disorder Society wishes to acknowledge and thank the following companies for their support: DOUBLE PLATINUM LEVEL Rome, Italy PLATINUM PLUS LEVEL PLATINUM LEVEL GOLD LEVEL BRONZE LEVEL 4 8TH INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS CONGRESS OF PARKINSON’S DISEASE 8TH INTERNATIONAL ORGANIZATION The Movement Disorder Society (MDS) is an international, PURPOSE, MISSION AND GOALS professional society of clinicians, scientists, and other Purpose: healthcare professionals, who are interested in Parkinson’s The object and mission of the Society shall be to advance the disease, related neurodegenerative and neurodevelopmental neurological sciences pertaining to Movement Disorders; to disorders, hyperkinetic Movement Disorders, and abnormali- operate exclusively for scientific, scholarly and educational ties in muscle tone and motor control. The spectrum of clinical purposes; to encourage research; to provide forums, such as disorders represented by the Society includes but is not medical journals, scientific symposia and International limited to: Congresses, for sharing ideas and for advancing the related Ataxia clinical and scientific disciplines; to encourage interest and Blepharospasm participation in the activities of the Society among healthcare Dysphonia and allied professionals and scientists; and to collaborate with Dystonic disorders other related professional and lay organizations. Gait disorders Huntington’s disease Mission and Goals: Myoclonus To disseminate knowledge about Movement Disorders by: Parkinson’s disease • Providing educational programs for clinicians, scientists Spasticity and the general public designed to advance scientific and Tardive dyskinesia clinical knowledge about Movement Disorders Tics and Tourette syndrome • Sponsoring congresses and symposia on Movement Tremor Disorders The Movement Disorder Society (MDS) was founded in 1985 • Collaborating with other international organizations and on the initiative of Professors Stanley Fahn and C. David lay groups Marsden, whose leadership and vision guided the expansion • Publishing journals, videotapes and other collateral of clinical expertise and research in this field. The organiza- materials committed to high scientific standards and peer tion merged in 1988 with the International Medical Society review for Motor Disturbances. To promote research into causes, prevention and treatment of Movement Disorders by: • Using the Society’s influence and resources to enhance support for research • Facilitating the dissemination of information about research • Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders To formulate and promote public policy that will favorably affect the care of patients with Movement Disorders by: • Working with regulatory agencies to assist them in the approval process of safe and effective therapeutic interven- tions • Informing the public (media) and patient support groups of new research and therapeutic advances • Playing a proactive role in the development of policies that affect support of research and patient care • Developing standards of training in the specialty 5 THE MOVEMENT DISORDER SOCIETY ORGANIZATION MDS OFFICERS Congress Organizing Committee President Chair: Alfredo Berardelli, Italy C. Warren Olanow, USA Giovanni Abbruzzese, Italy Alberto Albanese, Italy President-Elect Paolo Barone, Italy Andrew J. Lees, United Kingdom Ubaldo Bonuccelli, Italy Carlo Colosimo, Italy Secretary Rome, Italy Giovanni Fabbrini, Italy Andres M. Lozano, Canada Mario Manfredi, Italy Stefano Ruggieri Italy Secretary-Elect Fabrizio Stocchi, Italy Philip D. Thompson, Australia Mario Zappia, Italy Treasurer Past Presidents Wolfgang H. Oertel, Germany 2001-2002 Werner Poewe, Austria Treasurer-Elect 1999-2000 Mark Hallett, USA Daniel Tarsy, USA 1997-1998 Eduardo Tolosa, Spain 1995-1996 Joseph Jankovic, USA Past President 1991-1994 C. David Marsden, United Kingdom Werner Poewe, Austria 1988-1991 Stanley Fahn, USA International Executive Committee International Medical Society for Motor Paul J. Bédard, Canada Disturbances Francisco Cardoso, Brazil Past Presidents Cynthia L. Comella, USA 1993-1994 C. Warren Olanow, USA Santiago Giménez-Roldán, Spain 1991-1992 Bastian Conrad, Germany Nir Giladi, Israel 1989-1990 Mark Hallett, USA Ann M. Graybiel, USA 1987-1988 Mario Manfredi, Italy Yoshikuni Mizuno, Japan 1985-1986 C. David Marsden, United Kingdom Kapil D. Sethi, USA Caroline M. Tanner, USA MDS International Secretariat Marie Vidailhet, France The Movement Disorder Society 555 East Wells Street, 11th Floor International Congress Oversight Committee Milwaukee, WI 53202-3823 Chair: Mark Hallett, USA USA Wolfgang H. Oertel, Germany Tel: +1 414-276-2145 C. Warren Olanow, USA Fax: +1 414-276-3349 Werner Poewe, Austria E-mail: [email protected] Eduardo Tolosa, Spain Web site: www.movementdisorders.org Congress Scientific Program Committee ARISTEA - Local Organizing Secretariat Chair: C. Warren Olanow, USA Via Tolmino, 5 - 00198 Rome, Italy Co-Chair 2004: Anthony H.V.
Recommended publications
  • Levomilnacipran for the Treatment of Major Depressive Disorder
    Out of the Pipeline Levomilnacipran for the treatment of major depressive disorder Matthew Macaluso, DO, Hala Kazanchi, MD, and Vikram Malhotra, MD An SNRI with n July 2013, the FDA approved levomil- Table 1 once-daily dosing, nacipran for the treatment of major de- Levomilnacipran: Fast facts levomilnacipran pressive disorder (MDD) in adults.1 It is I Brand name: Fetzima decreased core available in a once-daily, extended-release formulation (Table 1).1 The drug is the fifth Class: Serotonin-norepinephrine reuptake symptoms of inhibitor serotonin-norepinephrine reuptake inhibi- MDD and was well Indication: Treatment of major depressive tor (SNRI) to be sold in the United States disorder in adults tolerated in clinical and the fourth to receive FDA approval for FDA approval date: July 26, 2013 trials treating MDD. Availability date: Fourth quarter of 2013 Levomilnacipran is believed to be the Manufacturer: Forest Pharmaceuticals more active enantiomer of milnacipran, Dosage forms: Extended–release capsules in which has been available in Europe for 20 mg, 40 mg, 80 mg, and 120 mg strengths years and was approved by the FDA in Recommended dosage: 40 mg to 120 mg 2009 for treating fibromyalgia. Efficacy of capsule once daily with or without food levomilnacipran for treating patients with Source: Reference 1 MDD was established in three 8-week ran- domized controlled trials (RCTs).1 cial and occupational functioning in addi- Clinical implications tion to improvement in the core symptoms Levomilnacipran is indicated for treating of depression.5
    [Show full text]
  • Country and City Arto Paasilinna – the Year of the Hare Keywords
    Country and City Arto Paasilinna – The Year of the Hare Keywords Arto Paasilinna (1942-) Country/City/Village Nature/Culture Tradition/Modernity Arto Paasilinna Arto Paasilinna was born in 1942, one of four famous ‘author brothers’ (Erno, Reino, and Mauri) whose family came from the Petsamo district of Finland, from which they resettle. Paasilinna is known for his satires, which use exaggeration and invention to mock aspirations and expectations of Finland’s urban middle class, and which are popular literature that does not fit into the ‘high’ literary tradition of Finnish culture. (http://en.wikipedia.org/wiki/Pechengsky_District) Country/Village/City Finland is a sparsely populated country, with large forests, especially in the north. Today, many Finns prize time spent in the countryside (maaseutu) or in lake country, picking berries and mushrooms, spending time at summer cottages, and doing outdoor activities and sports. Love of nature has its roots in agrarian society, and its basic social unit the village. The village (kylä) denominates a small cluster of farms and homes, often built according to the agricultural practice and geographical features. The village is a form of intimate, face-to-face social organization, a form of quasi-feudal economic organization, and a unit of administrative organization, as the church and state taxed the population through village units up through the early twentieth. During the 19th and 20th century, voluntaristic and political organizations, such as volunteer fire departments and lending libraries, came to be important parts of village social life. The city (kaupunki) is dense population center organized around economic and political activities and institutions, and governed by special rules and rights, which stand in contrast to a less populated countryside.
    [Show full text]
  • SSAB's Docol® Tubes in Gacha All-Weather Autonomous Shuttle
    SSAB’s Docol® Tubes in Gacha all-weather autonomous shuttle bus Esko Hakamäki, Product Manager, SSAB AGENDA DOCOL TUBES IN GACHA BUS DOCOL – AUTOMOTIVE STEEL SUMMARY LEADING PRODUCER OF ADVANCED HIGH-STRENGTH STEELS FOR OVER 40 YEARS ABOUT 14 300 EMPLOYEES IN 50 COUNTRIES NORDIC AND US-BASED STEEL COMPANY OUR BRANDED PRODUCT OFFER . SSAB DOMEX / BORON FORM / WEATHERING LASER PLUS A game Hard and The Better tool Hardest For harsh Optimized changer in tough for automotive performance steel for weather and families steel maximum steel maximum greener performance uptime protection living OUR AUTOMOTIVE BRAND SSAB DOMEX / BORON FORM / WEATHERING LASER PLUS A game- Hard and The Better tool Hardest For harsh Optimized changer in tough for Automotive performance steel for weather and families steel maximum steel maximum greener performance uptime protection living PRODUCTION SITES FOR AUTOMOTIVE STEEL BORLÄNGE, SWEDEN HOT ROLLING MILL COLD ROLLING MILL R&D CENTER HÄMEENLINNA, FINLAND METAL COATING LINE TUBE MILL R&D CENTER DOCOL TUBES IN GACHA BUS SSAB’S DOCOL® TUBES IN GACHA ALL- WEATHER AUTONOMOUS SHUTTLE BUS SSAB is a partner in the Gacha all-weather autonomous shuttle bus premiered in Helsinki in March. The autonomous minibus is the outcome of collaboration between Finnish robotics company Sensible 4 and the Japanese company MUJI. SSAB provided its expertise in special steels to the project by donating tubes made of Docol® steel for the bus frame to give the lightness required. SSAB’S DOCOL® TUBES IN GACHA ALL- WEATHER AUTONOMOUS SHUTTLE BUS
    [Show full text]
  • Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex
    Title Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex Author(s) Tsutsui-Kimura, Iku; Yoshida, Takayuki; Ohmura, Yu; Izumi, Takeshi; Yoshioka, Mitsuhiro International journal of neuropsychopharmacology, 18(5), pyu083 Citation https://doi.org/10.1093/ijnp/pyu083 Issue Date 2015-03 Doc URL http://hdl.handle.net/2115/59283 Rights(URL) http://creativecommons.org/licenses/by-nc/4.0 Type article File Information pyu083.full.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP International Journal of Neuropsychopharmacology, 2015, 1–14 doi:10.1093/ijnp/pyu083 Research Article research article Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex Iku Tsutsui-Kimura, PhD; Takayuki Yoshida, PhD; Yu Ohmura, PhD; Takeshi Izumi, MD, PhD; Mitsuhiro Yoshioka, MD, PhD Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Sapporo, Japan (Drs Tsutsui-Kimura, Yoshida, Ohmura, Izumi, and Yoshioka); Japan Society for the Promotion of Science, Tokyo, Japan (Dr Tsutsui-Kimura); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Dr Tsutsui-Kimura). Correspondence: Yu Ohmura, PhD, Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo, 060-8638, Japan ([email protected]). Abstract Background: Deficits in impulse control are often observed in psychiatric disorders in which abnormalities of the prefrontal cortex are observed, including attention-deficit/hyperactivity disorder and bipolar disorder. We recently found that milnacipran, a serotonin/noradrenaline reuptake inhibitor, could suppress impulsive action in normal rats. However, whether milnacipran could suppress elevated impulsive action in rats with lesions of the ventromedial prefrontal cortex, which is functionally comparable with the human prefrontal cortex, remains unknown.
    [Show full text]
  • LUETTELO Kuntien Ja Seurakuntien Tuloveroprosenteista Vuonna 2021
    Dnro VH/8082/00.01.00/2020 LUETTELO kuntien ja seurakuntien tuloveroprosenteista vuonna 2021 Verohallinto on verotusmenettelystä annetun lain (1558/1995) 91 a §:n 3 momentin nojalla, sellaisena kuin se on laissa 520/2010, antanut seuraavan luettelon varainhoitovuodeksi 2021 vahvistetuista kuntien, evankelis-luterilaisen kirkon ja ortodoksisen kirkkokunnan seurakuntien tuloveroprosenteista. Kunta Kunnan Ev.lut. Ortodoks. tuloveroprosentti seurakunnan seurakunnan tuloveroprosentti tuloveroprosentti Akaa 22,25 1,70 2,00 Alajärvi 21,75 1,75 2,00 Alavieska 22,00 1,80 2,10 Alavus 21,25 1,75 2,00 Asikkala 20,75 1,75 1,80 Askola 21,50 1,75 1,80 Aura 21,50 1,35 1,75 Brändö 17,75 2,00 1,75 Eckerö 19,00 2,00 1,75 Enonkoski 21,00 1,60 1,95 Enontekiö 21,25 1,75 2,20 Espoo 18,00 1,00 1,80 Eura 21,00 1,50 1,75 Eurajoki 18,00 1,60 2,00 Evijärvi 22,50 1,75 2,00 Finström 19,50 1,95 1,75 Forssa 20,50 1,40 1,80 Föglö 17,50 2,00 1,75 Geta 18,50 1,95 1,75 Haapajärvi 22,50 1,75 2,00 Haapavesi 22,00 1,80 2,00 Hailuoto 20,50 1,80 2,10 Halsua 23,50 1,70 2,00 Hamina 21,00 1,60 1,85 Hammarland 18,00 1,80 1,75 Hankasalmi 22,00 1,95 2,00 Hanko 21,75 1,60 1,80 Harjavalta 21,50 1,75 1,75 Hartola 21,50 1,75 1,95 Hattula 20,75 1,50 1,80 Hausjärvi 21,50 1,75 1,80 Heinola 20,50 1,50 1,80 Heinävesi 21,00 1,80 1,95 Helsinki 18,00 1,00 1,80 Hirvensalmi 20,00 1,75 1,95 Hollola 21,00 1,75 1,80 Huittinen 21,00 1,60 1,75 Humppila 22,00 1,90 1,80 Hyrynsalmi 21,75 1,75 1,95 Hyvinkää 20,25 1,25 1,80 Hämeenkyrö 22,00 1,70 2,00 Hämeenlinna 21,00 1,30 1,80 Ii 21,50 1,50 2,10 Iisalmi
    [Show full text]
  • Tulomuutto KUUMA-Kuntiin 2014 Tulomuutto KUUMA-Kuntiin 2013
    Tulomuutto KUUMA-kuntiin 2014 Tulo - Tulo - Tulo - Tulo - Tulo - Lähtökunta Hyvinkää Lähtökunta Järvenpää Lähtökunta Kerava Lähtökunta Kirkko-nummi Lähtökunta Mäntsälä KOKO MAA 2364 KOKO MAA 2647 KOKO MAA 2544 KOKO MAA 2275 KOKO MAA 1070 Helsinki 300 Helsinki 505 Vantaa 619 Espoo 858 Helsinki 157 Nurmijärvi 224 Vantaa 373 Helsinki 510 Helsinki 472 Vantaa 144 Riihimäki 182 Tuusula 355 Tuusula 283 Vantaa 138 Järvenpää 124 Vantaa 174 Kerava 270 Järvenpää 165 Siuntio 80 Tuusula 93 Espoo 122 Mäntsälä 146 Espoo 124 Vihti 41 Kerava 58 Tuusula 122 Espoo 130 Sipoo 95 Tampere 40 Lahti 47 Tulo - Tulo - Tulo - Lähtökunta Nurmijärvi Lähtökunta Pornainen Lähtökunta Sipoo Lähtökunta Tulo - Tuusula Lähtökunta Tulo - Vihti KOKO MAA 2171 KOKO MAA 304 KOKO MAA 986 KOKO MAA 2307 KOKO MAA 1498 Helsinki 526 Järvenpää 47 Helsinki 326 Vantaa 536 Helsinki 286 Vantaa 486 Vantaa 42 Vantaa 184 Helsinki 433 Espoo 283 Espoo 254 Helsinki 42 Porvoo - Borgå 75 Järvenpää 287 Lohja - Lojo 211 Hyvinkää 131 Tuusula 25 Kerava - Kervo 69 Kerava - Kerv 223 Vantaa 124 Tuusula 57 Kerava - Kervo 21 Espoo 57 Espoo 95 Karkkila - Hö 88 Vihti 47 Sipoo - Sibbo 18 Järvenpää 50 Hyvinkää - H 85 Kirkkonumm 75 Tulomuutto KUUMA-kuntiin 2013 Tulo - Tulo - Tulo - Tulo - Tulo - Lähtökunta Hyvinkää Lähtökunta Järvenpää Lähtökunta Kerava Lähtökunta Kirkko-nummi Lähtökunta Mäntsälä KOKO MAA 2641 KOKO MAA 2556 KOKO MAA 2594 KOKO MAA 2081 KOKO MAA 1097 Helsinki 329 Helsinki 478 Vantaa 543 Espoo 820 Helsinki 166 Nurmijärvi 245 Vantaa 344 Helsinki 491 Helsinki 467 Järvenpää 164 Riihimäki 217 Tuusula
    [Show full text]
  • Study Visit Helsinki-Espoo – 14-16 March 2016 Practical Information 1
    Study visit Helsinki-Espoo – 14-16 March 2016 Practical information Note: hotel and subsistence costs are covered by Culture for cities and regions. On your day of arrival, we will reimburse your dinner if it does not exceed €25. Remember to keep all originals of your receipts, invoices, proofs of purchase to get reimbursed. Please also keep your boarding passes. 1. Travelling to and around Helsinki Please use public transports during your stay in Helsinki. We will reimburse trains and airport shuttle tickets after the study visit. The use of taxis should be as limited as possible. Helsinki airport – Helsinki-Vantaa (HEL) The new Ring Rail Line provides a rail link between Helsinki-Vantaa Airport and Helsinki Central railway station. Trains run every 10 minutes in the daytime. The line is served by the "P" and "I" trains which travel the ring clockwise and counter-clockwise respectively. The journey time from the airport to Helsinki Central Railway Station is 27 minutes ("P" train) or 32 minutes ("I" train). Operating hours: Every 10 minutes Monday-Friday 9am-7pm, Saturday 9am-4pm Every 15 minutes Monday-Friday 7pm10pm, Saturday 7am-9am and 7pm-10pm, Sunday 10am-10pm Every 20 minutes Monday-Friday 4am-6am and 10pm-midnigth, Saturday 5am-7am and 10pm-midnigt, Sunday 5am-10am and 10pm-midnight A ticket for the Ring Rail Line costs: 5.50€(regional train ticket) 1 Taxis from the airport Please note that the use of taxis should be as limited as possible: take public transport whenever you can, as we will reimburse taxi costs only if justified.
    [Show full text]
  • CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology
    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology Generic Name (Brand Name) Cidofovir (Vistide) Acetaminophen/butalbital (Allzital; Citalopram (Celexa) Bupap) Clomipramine (Anafranil) Acetaminophen/butalbital/caffeine Clonidine (Catapres; Kapvay) (Fioricet; Butace) Clorazepate (Tranxene-T) Acetaminophen/butalbital/caffeine/ Clozapine (Clozaril; FazaClo; Versacloz) codeine (Fioricet with codeine) Cyclizine (No Brand Name) Acetaminophen/caffeine (Excedrin) Cyclobenzaprine (Flexeril) Acetaminophen/caffeine/dihydrocodeine Desipramine (Norpramine) (Panlor; Trezix) Desvenlafaxine (Pristiq; Khedezla) Acetaminophen/tramadol (Ultracet) Dexmethylphenidate (Focalin) Aliskiren (Tekturna) Dextroamphetamine (Dexedrine; Amitriptyline (Elavil) ProCentra; Zenzedi) Amitriptyline and chlordiazepoxide Dextroamphetamine and amphetamine (Limbril) (Adderall) Amoxapine (Asendin) Diazepam (Valium; Diastat) Aripiprazole (Abilify) Diethylpropion (No Brand Name) Armodafinil (Nuvigil) Dimenhydrinate (Dramamine) Asenapine (Saphris) Donepezil (Aricept) Aspirin/caffeine (BC Powder; Goody Doripenem (Doribax) Powder) Doxapram (Dopram) Atomoxetine (Strattera) Doxepin (Silenor) Baclofen (Gablofen; Lioresal) Droperidol (No Brand Name) Benzphetamine (Didrex; Regimex) Duloxetine (Cymbalta) Benztropine (Cogentin) Entacapone (Comtan) Bismuth Ergotamine and caffeine (Cafergot; subcitrate/metronidazole/tetracycline Migergot) (Pylera) Escitalopram (Lexapro) Bismuth subsalicylate (Pepto-Bismol) Fluoxetine (Prozac; Sarafem)
    [Show full text]
  • Milnacipran for Pain in Fibromyalgia in Adults
    Milnacipran for pain in fibromyalgia in adults (Review) Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 10 http://www.thecochranelibrary.com Milnacipran for pain in fibromyalgia in adults (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 9 Figure1. ..................................... 10 Figure2. ..................................... 12 Figure3. ..................................... 13 Figure4. ..................................... 14 Figure5. ..................................... 18 DISCUSSION ..................................... 21 AUTHORS’CONCLUSIONS . 22 ACKNOWLEDGEMENTS . 23 REFERENCES ..................................... 23 CHARACTERISTICSOFSTUDIES . 27 DATAANDANALYSES. 38 Analysis 1.1. Comparison 1 Milnacipran 100 mg/day versus placebo, Outcome 1 At least 30% pain relief. 39 Analysis 1.2. Comparison 1 Milnacipran 100 mg/day versus placebo, Outcome 2 PGIC ’much improved’ or ’very much improved’.................................... 40 Analysis 1.3. Comparison
    [Show full text]
  • Efficacy of Milnacipran in Patients with Fibromyalgia R
    Efficacy of Milnacipran in Patients with Fibromyalgia R. MICHAEL GENDREAU, MICHAEL D. THORN, JUDY F. GENDREAU, JAY D. KRANZLER, SAULO RIBEIRO, RICHARD H. GRACELY, DAVID A. WILLIAMS, PHILIP J. MEASE, SAMUEL A. McLEAN, and DANIEL J. CLAUW ABSTRACT. Objective. Fibromyalgia (FM) is a common musculoskeletal condition characterized by widespread pain, tenderness, and a variety of other somatic symptoms. Current treatments are modestly effec- tive. Arguably, the best studied and most effective compounds are tricyclic antidepressants (TCA). Milnacipran, a nontricyclic compound that inhibits the reuptake of both serotonin and norepineph- rine, may provide many of the beneficial effects of TCA with a superior side effect profile. Methods. One hundred twenty-five patients with FM were randomly assigned in a 3:3:2 ratio to receive milnacipran twice daily, milnacipran once daily, or placebo for 3 months in a double-blind dose-escalation trial; 92% of twice-daily and 81% of once-daily participants achieved dose escala- tion to the target milnacipran dose of 200 mg. Results. The primary endpoint was reduction of pain. Both the once- and twice-daily groups showed statistically significant improvements in pain, as well as improvements in global well being, fatigue, and other domains. Response rates for patients receiving milnacipran were equal in patients with and without comorbid depression, but placebo response rates were considerably higher in depressed patients, leading to significantly greater overall efficacy in the nondepressed group. Conclusion. In this Phase II study, milnacipran led to statistically significant improvements in pain and other symptoms of FM. The effect sizes were equal to those previously found with TCA, and the drug was generally well tolerated.
    [Show full text]
  • Anticonvulsants Antipsychotics Benzodiazepines/Anxiolytics ADHD
    Anticonvulsants Antidepressants Generic Name Brand Name Generic Name Brand Name Carbamazepine Tegretol SSRI Divalproex Depakote Citalopram Celexa Lamotrigine Lamictal Escitalopram Lexapro Topirimate Topamax Fluoxetine Prozac Fluvoxamine Luvox Paroxetine Paxil Antipsychotics Sertraline Zoloft Generic Name Brand Name SNRI Typical Desvenlafaxine Pristiq Chlorpromazine Thorazine Duloextine Cymbalta Fluphenazine Prolixin Milnacipran Savella Haloperidol Haldol Venlafaxine Effexor Perphenazine Trilafon SARI Atypical Nefazodone Serzone Aripiprazole Abilify Trazodone Desyrel Clozapine Clozaril TCA Lurasidone Latuda Clomimpramine Enafranil Olanzapine Zyprexa Despiramine Norpramin Quetiapine Seroquel Nortriptyline Pamelor Risperidone Risperal MAOI Ziprasidone Geodon Phenylzine Nardil Selegiline Emsam Tranylcypromine Parnate Benzodiazepines/Anxiolytics DNRI Generic Name Brand Name Bupropion Wellbutrin Alprazolam Xanax Clonazepam Klonopin Sedative‐Hypnotics Lorazepam Ativan Generic Name Brand Name Diazepam Valium Clonidine Kapvay Buspirone Buspar Eszopiclone Lunesta Pentobarbital Nembutal Phenobarbital Luminal ADHD Medicines Zaleplon Sonata Generic Name Brand Name Zolpidem Ambien Stimulant Amphetamine Adderall Others Dexmethylphenidate Focalin Generic Name Brand Name Dextroamphetamine Dexedrine Antihistamine Methylphenidate Ritalin Non‐stimulant Diphenhydramine Bendryl Atomoxetine Strattera Anti‐tremor Guanfacine Intuniv Benztropine Cogentin Mood stabilizer (bipolar treatment) Lithium Lithane Never Mix, Never Worry: What Clinicians Need to Know about
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]